Pharmaceutical Technology, Oct 2, 2010 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Oct 2, 2010
Online Exclusives
The Role of the Qualified Person in European Pharmaceutical Regulations
By Bernd Renger , Oliver Schmidt
The authors provide a brief overview of the European pharmaceutical regulation with regard to batch certification by a qualified person and batch release for the European market.
Novartis's Influenza Vaccine Program: A conversation with Matthew Stober, global head of technical operations for Novartis
By Michelle Hoffman
Novartis' Matthew Stober discusses vaccine manufacturing, including egg- and cell-based systems.
Pfizer Outlines Biomanufacturing Strategy
By Patricia Van Arnum
Pfizer's acquisition of Wyeth involves augmenting its biopharmaceutical product portfolio, pipeline, and related development and manufacturing capabilities.
An Unfocused Handbook on Environmental Monitoring
By Roger Dabbah
An expert-panel-written book has surprising shortcomings.
Special Report
Vaccine Manufacturing Reborn
By Michelle Hoffman
Drugmakers hatch new manufacturing paradigms in the wake of the 2009 H1N1 influenza pandemic.
The Direction of Injectable Drug Delivery
By Patricia Van Arnum
The growth of biologics is an important factor for the injectable-drug delivery systems market. A look at the technical and market considerations affecting this sector.
Peer-Reviewed
An Overview of NanoCluster Powder Formulation Technology
By Cory Berkland , George Laurence , Stephen Lermer , Michael Crowley
The authors describe a technique designed to yield low-density powders with a tailored particle-size distribution over a broad range of respiratory flow rates.
Formulation and Evaluation of an Effervescent, Gastroretentive Drug-Delivery System
By A. Nanda , M. Ola , R. Bhaskar , C.K. Sharma , S. Nayak
The authors developed a formulation for effervescent gastroretentive drug delivery techniques using ibuprofen as a model drug. They optimized the formulations by applying full factorial design.
From The Editor
This Again?
By Michelle Hoffman
The reopened debate over embryonic-stem-cell research could stifle many other scientific pursuits.
PharmTech Talk
Needles' Days Are Numbered
By Erik Greb
Private companies and universities are developing new ways to deliver protein drugs.
Agent-in Place
Communication Quandaries
By Control
From disagreement to denial, being cordial about quality control can be challenging.
News
Report from Europe
By Sean Milmo
Public-private R&D partnerships are on the rise across Europe, but national goals and academia-industry competition could prevent their success at the European level.
Global Healthcare on the Ground: The PATH Malaria Vaccine Initiative
By Angie Drakulich
A look at MVI's malaria work in developing countries.
In the Spotlight
In the Spotlight
Editors' picks of pharmaceutical science and technology innovations.
Washington Report
Administration Seeks to Modernize Vaccine Production
By Jill Wechsler
President Obama and HHS eye innovation and countermeasures to protect public health.
Ingredients Insider
Risk Mitigation in High-Potency Manufacturing
By Patricia Van Arnum
A recently released industry guide outlines a science- and risk-based approach to control the risk of cross-contamination.
Inside EDQM
Inside EDQM: Active Ingredient Inspection and Certification
By Susanne Keitel
The EDQM inspection program helps to ensure the quality of APIs on the European market.
Outsourcing Outlook
Buyers in Short Supply
By Jim Miller
Global pharmaceutical companies could have a problem getting rid of redundant facilities.
Industry Leaders
Q&A with Gibraltar Laboratories
The president of Gibraltar Laboratories, Daniel Prince, discusses industry trends and challenges.
Viewpoint
To Label or Not to Label
By Frederick J. Balboni, Jr. , Shawn C. Becker
In light of compendial changes, representatives of the US Pharmacopeia and an industry consortium provide perspectives on cap and ferrule labels.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Click here